Contact us

    MrMrsMsDr



    Collection and Use of Personal Information. *

    Author: Deepbio

    Deep Bio to Present Their Research Findings at The Poster Sessions During the USCAP 113th Annual Meeting

    Posted on by Deepbio

    SEOUL, SOUTH KOREA, March 19, 2024 /EINPresswire.com/ — Four research results will be presented to validate Deep Bio’s pioneering research and breakthroughs in AI advancements in digital pathology.
    Link to the Article 

    Deep Bio, a leader in AI-driven solutions for cancer diagnostics, announced that four different research results will be presented at the poster presentations during the 2024 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, to be held in Baltimore from March 23 to March 28. The posters will describe Deep Bio’s pioneering advancements in AI-driven pathology, demonstrating how novel AI techniques enhance the company’s expertise across diverse tissue and cancer types.

    Sun Woo Kim, CEO of Deep Bio, said, “With the increasing demand for advanced medical technologies based on AI, digital pathology has recently emerged as a significant topic. We proudly present the meaningful research results of deep-learning-based cancer diagnosis at the world-class pathology conference for six consecutive years since 2018. We will continue our research to ensure that our deep learning technology contributes to a new era of diagnosis, ranging from cancer diagnosis and prognosis to treatment, across various types of cancer.”

    Innovative Research Highlights at USCAP:

    • Poster Presentation (#167): A Deep Learning-Based Tumor Area Identification Using a Semi-Supervised Approach for IHC Stained Images in Non-Small Lung Carcinoma
    o Session Date & Time: March 25, 2024, From 1:00 to 4:30 p.m.
    o Lead Author: Yunseob Hwang
    o Overview: This research evaluates a semi-supervised approach to cancer area detection models in cMET IHC-stained whole slide images (WSIs) of non-small cell lung cancer (NSCLC). Manually delineating entire cancer areas in large tissues like resection slides remains a labor-intensive task for developing AI models. Due to this fact, this research introduces a simple yet effective semi-supervised learning approach for tumor area segmentation deep learning models using IHC stained images.

    • Poster Presentation(#180): Enhancing Multi-organ: Frozen Section Cancer Discrimination Model with Additional Formalin-Fixed Paraffin-Embedded Whole Slide Images
    o Session Date & Time: March 26, from 9:30 to 12:00 p.m.
    o Lead Author: Joonho Lee
    o Overview: This research explores the automated analysis of H&E-stained Frozen Section (FS) WSIs using a deep learning model across various tissue types to enhance the accuracy of FS cancer discrimination. This deep-learning model is specially developed to determine the presence of cancer in H&E-stained FS whole slide images in the Breast, Lung, Stomach, Breast Sentinel Lymph Node, and Prostate, using H&E-stained and Formalin-Fixed Paraffin-Embedded (FFPE) WSIs.

    • Poster Presentation(#210): Enhancing Frozen Section Whole Slide image classification by Style transfer with CycleGAN
    o Session Date & Time: March 27, from 1:00 to 4:30 p.m.
    o Lead Author: Junho Lee
    o Overview: This research introduces a style transfer model to transform the delineation of FFPE data into Frozen Section (FS) data, enriching the data and enhancing feature discrimination. Unlike the Formalin-Fixed Paraffin-Embedded (FFPE) tissue slides, the FS Whole Slide Image (WSI) often has low slide quality due to artifacts, leading to inferior prediction performance compared to the FFPE WSI. Therefore, training-styled-transferred FFPE slides can enhance the predictive performance of FS slides at the slide level and improve the discriminative feature of patch-level images.

    • Poster Presentation(#173): Storage Optimization for Digital Pathology Images: Super-Resolution based image compression
    o Session Date & Time: March 26, from 9:30 to 12:00 p.m.
    o Lead Author: Soyeon Jang
    o Overview: This research proposes a super-resolution-based image compression technique to reduce storage demands without sacrificing image quality since storing large volumes of digital pathology data requires monetary investment for institutions to process high caseloads.

    About Deep Bio

    Deep Bio is an AI healthcare company dedicated to advancing the field of cancer pathology. Focusing on deep learning, the company develops cutting-edge In Vitro Diagnostic Software as Medical Devices (IVD SaMDs) to empower pathologists and medical professionals with state-of-the-art tools for more accurate cancer diagnosis and prognosis. Deep Bio is committed to improving cancer treatment decisions and patient outcomes by harnessing the power of artificial intelligence.

    For more information, visit the website: www.deepbio.co.kr.

    Deep Bio’s DeepDx Prostate Featured in CancerX’s Solutions Catalog, Pioneering Digital Innovation in Oncology

    Posted on by Deepbio

    SEOUL, SOUTH KOREA, February 5, 2024 /EINPresswire.com/ — Deep Bio, a pioneer of AI-powered cancer diagnostics solutions, proudly announced the inclusion of DeepDx Prostate in CancerX’s Solutions Catalog. This significant participation positions Deep Bio as a key contributor to CancerX’s inaugural project, which is dedicated to dismantling barriers to digital innovation in oncology.

    Link to the Article 

    The Solutions Catalog, launched in 2023, represents CancerX’s inaugural concrete initiative, strategically designed for digital transformation to enhance access to cancer care and alleviate financial burdens on patients.

    The Solutions Catalog, an integral part of CancerX’s groundbreaking project, is segmented into three key areas: Screening/Diagnosis, Treatment/End-of-Life Care, and Survivorship. It acts as a reference guide showcasing commercialized digital products and solutions in medical institutions across the United States. The CancerX project ensures immediate access to cutting-edge digital cancer diagnostics and treatment solutions from the featured companies in the Solutions Catalog for healthcare organizations nationwide.

    The latest update of the CancerX Solutions Catalog features Deep Bio’s AI-powered software, DeepDx Prostate. This groundbreaking solution empowers pathologists to deliver more precise and efficient prostate diagnoses by automating prostate cancer lesion identification, grading, and quantification of tumor proportion measurements. The solution also significantly decreases turnaround times, minimizes subjectivity in diagnosis, and reduces costs associated with overdiagnosis or unnecessary treatments. These groundbreaking features have immense potential to reduce health inequities in cancer care access and alleviate financial strains on patients.

    Sun Woo Kim, CEO of Deep Bio, highlights the urgency of tackling prostate cancer, the second-leading cause of death among American men. “The innovative features of DeepDx Prostate have immense potential to reduce health inequities in cancer care access and alleviate financial strains on patients,” Kim emphasizes the positive impacts of DeepDx Prostate in the medical field. “Due to that fact, Deep Bio’s listing in the Solutions Catalog signifies a transformation of the diagnostic landscape but also contributes to escalating the quality of medical services for prostate cancer patients,” he said.

    Deep Bio is proud to contribute to CancerX’s mission of advancing cancer care through innovative digital solutions. The collaboration underscores a shared commitment to improving patient outcomes and enhancing the overall landscape of cancer diagnostics and treatment.

    For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.

    Deep Bio Announces Launch of DeepDx Prostate in Switzerland, Paving the Way for European Expansion

    Posted on by Deepbio

    SEOUL, SOUTH KOREA, JANUARY 31, 2024 / PRNewswire/ – Deep Bio’s AI-powered Prostate Cancer Diagnostic Software is Now Available on the Swiss Market, Advancing Healthcare Access Across Europe.

    Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, proudly announced the availability of its CE-marked in-vitro diagnostic device, DeepDx Prostate, on the Swiss market.
    This strategic market expansion and product launch signify a significant milestone in Deep Bio’s roadmap for expanding its footprint in Europe.

    Link to the Article

    DeepDx Prostate is an AI-powered software for the assessment of prostate cancer on digital whole slide images of hematoxylin and eosin-stained prostate core-needle biopsies. By automating the identification, grading, and quantification of cancerous lesions, this diagnostic software empowers pathologists to make more accurate and efficient prostate cancer diagnoses, reducing subjectivity and turnaround times. DeepDx Prostate is the first in Deep Bio’s suite of diagnostic software products that aim to enhance diagnostic accuracy and in turn, optimize clinical management and patient outcomes.

    “We are excited to introduce DeepDx Prostate to Switzerland,” said Sun Woo Kim, the CEO and founder of Deep Bio. “Increasing the reach of DeepDx Prostate to additional countries underscores Deep Bio’s unwavering commitment to improving global access to high-quality healthcare and advancing prostate cancer diagnosis through AI-driven innovation.”

    Deep Bio continues to expand its global reach through partnerships with digital pathology leaders in the US, Europe, and India. The company conducts collaborative research with leading US research institutions, including Stanford Medical School and Harvard Dana-Farber Cancer Institute, with its clinical validation studies published in prestigious medical journals, such as Cancers and npj Digital Medicine.

    For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.

    About Deep Bio

    Deep Bio Inc. is an AI healthcare company with expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve the efficiency and accuracy of pathologic cancer diagnosis and prognosis.

    DeepDx® Prostate is a clinically-validated AI for the assessment of prostate cancer. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity. To learn more, visit https://www.deepbio.co.kr.

    Deep Bio becomes first Korean cancer diagnostic AI company to win CES Innovation Award

    Posted on by Deepbio

    SEOUL, SOUTH KOREA, NOVEMBER 21, 2023 / PRNewswire/ – Won the CES Innovation Award for pioneering a new milestone in Korean cancer diagnosis AI solutions.

    Link to the Article 

    Deep Bio announced today that it has been awarded the CES Innovation Award as the first Korean cancer diagnosis A.I. company in CES 2024, the world’s largest electronics exhibition, to be held in Las Vegas, USA, in the upcoming January.

    The Consumer Technology Association (CTA) today announced the products and technologies that won CES Innovation Awards. Deep Bio won the Innovation Award in the Digital Healthcare category, the first time the A.I. diagnostic-aid software company helped detect meaningful findings among cancer patients.

    Deep Bio recognizes this award as an achievement that demonstrates its world-class technology in cancer diagnosis and prognosis and raises the profile of Korean cancer diagnosis A.I. companies.

    Deep Bio leverages its expertise in deep learning and cancer pathology to provide state-of-the-art in vitro diagnostic software (IVDs, SaMDs) that analyzes various cancers’ cancerous areas and severity to help medical professionals make more informed decisions. As such, Deep Bio’s DeepDx Prostate has a high precision of 99% sensitivity and 97% specificity.

    “Deep Bio has proven its technical excellence both internally and externally, winning the silver medal at the Edison Awards in the United States, which is called the ‘Oscar of Innovation’ in 2021 and was won by Tesla’s Elon Musk and Apple’s Steve Jobs, as well as the first place in 2019 at the CAMELYON16 Challenge, which evaluates image recognition technology,” said Kim Sun-woo, CEO of Deep Bio. “We will strive to improve the cancer diagnosis environment and provide cutting-edge cancer diagnosis AI solutions to medical professionals through generous investment in technology to overcome the biggest challenge of humanity, cancer.”

    Meanwhile, CES 2024 will be held at the Las Vegas Convention Center in the United States from January 9th to 12th, and Deep Bio’s award can be searched on the CES Innovation Awards website.

    For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.

    About Deep Bio

    Deep Bio is an AI healthcare company focusing on deep learning to advance the field of cancer pathology. By developing cutting-edge in vitro diagnostic software (IVD SaMD), Deep Bio strives to provide pathologists and medical professionals with state-of-the-art diagnostic aids for more accurate cancer diagnosis and prognosis. Its main products include DeepDx Prostate, an AI software for prostate cancer analysis, which was the first in vitro diagnostic product to be approved by the Ministry of Food and Drug Safety in Korea. In 2019, the product won the Silver Award at the U.S. Edison Awards, which was won by Apple (2012) and Tesla (2014), and also won first place at the CAMELYON17 Challenge, a global AI digital pathology image analysis competition. In 2021, Deep Bio was recognized as one of the top 100 AI startups in Korea for the third year in a row, and has been recognized as a company that will lead the innovation of digital healthcare in the future.

    Deep Bio Joins CancerX to Revolutionize Cancer Diagnosis and Prognosis with AI Expertise

    Posted on by Deepbio

    SEOUL, SOUTH KOREA, NOVEMBER 7, 2023 / PRNewswire/ – Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation in the groundbreaking CancerX initiative, a public-private partnership unveiled earlier this year as part of the White House Cancer Moonshot program. This strategic partnership marks a significant milestone in the company’s mission to transform the landscape of cancer diagnosis and prognosis.

    Link to the Article 

    Deep Bio has been at the forefront of innovation in healthcare technology, leveraging its in-house expertise in deep learning and cancer pathology to develop cutting-edge solutions for the medical community. The company’s vision is to revolutionize the way cancer is diagnosed and treated by providing pathologists with state-of-the-art In Vitro Diagnostic Software as a Medical Device (IVD SaMDs) powered by deep learning algorithms. These advanced tools are set to significantly enhance the accuracy and efficiency of cancer diagnosis, enabling healthcare professionals to make more informed treatment decisions.

    Given that cancer is one of the most pressing global health challenges, CancerX assembles like-minded organizations and experts to collaborate on pioneering innovative solutions that will accelerate progress in cancer research, diagnosis, and treatment. Deep Bio is thrilled to be a part of this ambitious endeavor and is committed to deploying its expertise and resources to advance the fight against cancer.

    Sun Woo Kim, CEO and founder of Deep Bio, expressed his enthusiasm for this collaboration, stating, “Joining the CancerX program is a testament to our dedication to improving the lives of cancer patients and healthcare professionals. Our mission has always been to harness the power of artificial intelligence to provide more accurate, efficient, and accessible cancer diagnostics. This partnership with CancerX will amplify our impact and help us realize this vision.”

    “Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we’re honored to partner with Deep Bio to achieve the ambitious goals of CancerX,” said Smit Patel, Associate Program Director at Digital Medicine Society (DiMe). “Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey.”

    CancerX is known for uniting visionary companies and experts in a collective effort to conquer cancer through innovation, research, and advanced technology. Deep Bio will work closely with other participants to propel groundbreaking projects and develop solutions that will have a lasting impact on the fight against cancer.

    For more information, please visit Deep Bio’s website or contact sales@deepbio.co.kr.

    About Deep Bio

    Deep Bio is an AI healthcare company dedicated to advancing the field of cancer pathology. With a focus on deep learning, the company develops cutting-edge In Vitro Diagnostic Software as Medical Devices (IVD SaMDs) to empower pathologists and medical professionals with state-of-the-art tools for more accurate cancer diagnosis and prognosis. By harnessing the power of artificial intelligence, Deep Bio is committed to improving cancer treatment decisions and patient outcomes.

    Deep Bio Earns Coveted Spot in Korea AI Startup 100 List for the Third Consecutive Year

    Posted on by Deepbio

    Link to the Article 

    SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ — Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, announced today that it has been named to the Korea AI Startup 100 list. This prestigious list, representing a recognition of the nation’s most promising startups, marks the third consecutive year that Deep Bio has secured inclusion on this esteemed list.

    The Korea AI Startup 100 initiative seeks to recognize startups in Korea that are at the forefront of driving AI innovation. Candidate companies underwent rigorous evaluation by a panel of AI experts. The evaluation criteria, developed in partnership with the Korea Advanced Institute of Science and Technology (KAIST) and KT Economics & Management Research Institute, spanned quantitative factors such as market growth potential, corporate valuation, AI technology prowess, as well as qualitative aspects such as sustainability and corporate impact.

    “We are immensely honored to once again be recognized as a leading startup representing Korea. Our inclusion in the list for the third consecutive year is a validation of Deep Bio’s unwavering pursuit of innovation and the value we bring to the healthcare industry,” said Sun Woo Kim, founder and CEO of Deep Bio. “We remain committed to pioneering groundbreaking solutions that transform the landscape of digital pathology and cancer diagnostics.”

    Deep Bio pioneered AI-based pathology image analysis and cancer diagnosis research in Korea, leading the charge in the digital transformation of pathology. The company’s groundbreaking AI-based cancer diagnostic support software, DeepDx® Prostate, marks a significant milestone in the assessment of prostate cancer by empowering pathologists to make more precise and efficient diagnoses.

    On the global stage, Deep Bio is strategically expanding its footprint through partnerships with digital pathology platform providers across the United States, Europe, and India. The company also collaborates on groundbreaking research initiatives with esteemed institutions such as Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other leading research organizations in the United States. Deep Bio consistently shares its innovative research findings through publication in renowned medical journals, including Cancers and npj Digital Medicine.

    About Deep Bio

    Deep Bio Inc. is an AI healthcare company with expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve the efficiency and accuracy of pathologic cancer diagnosis and prognosis.

    DeepDx® Prostate is a clinically validated AI for the assessment of prostate cancer. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.

    Deep Bio Welcomes Grant Carlson as Chief Commercial Officer

    Posted on by Deepbio

    Seasoned Industry Expert Joins Deep Bio to Drive Commercial Growth and Expansion. Deep Bio appoints Grant Carlson as the company’s Chief Commercial Officer.

    SEOUL, SOUTH KOREA (PRWEB) JULY 30, 2023 – Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the appointment of Grant Carlson as its new Chief Commercial Officer (CCO). With over 30 years of experience in molecular diagnostics, biotechnology and life sciences industries, Carlson brings a wealth of knowledge to Deep Bio.

    In his new role, Carlson will be responsible for overseeing Deep Bio’s commercial strategy, driving business development, and expanding the company’s market presence globally. He will leverage his deep understanding of the pathology market and proven track record of driving exponential sales growth to further strengthen Deep Bio’s outreach and customer base.

    Prior to joining Deep Bio, Carlson held several executive roles in leading healthcare and biopharma companies. Notably, he served as the Chief Commercial Officer at PathAI Diagnostics, where he played a pivotal role in spearheading US sales and initiating commercial sales for remote workstations in the US, delivering significant growth.

    Carlson also held key leadership positions at NeoGenomics Laboratories and Dianon Systems, where he demonstrated his ability to drive rapid organizational growth in emerging markets through strategic partnerships and implementation of effective commercialization strategies.

    “We are thrilled to welcome Grant to the Deep Bio team,” said Sun Woo Kim, CEO and founder of Deep Bio. “His unparalleled experience and excellent track record in business development and commercial operations will be instrumental in accelerating growth. Grant’s deep understanding of the anatomic, clinical and digital pathology markets will play a crucial role in expanding our reach. Grant’s appointment marks a significant milestone in Deep Bio’s vision of transforming cancer diagnosis through our AI diagnostic solutions.”

    “I am honored and excited to join the Deep Bio team at this pivotal moment,” Carlson said. “I am thrilled to be part of a company that is revolutionizing cancer diagnosis and treatment worldwide by applying groundbreaking AI technologies to pathology diagnostics. The opportunity to make a profound impact on the lives of cancer patients is truly inspiring. I look forward to collaborating closely with the incredibly talented team at Deep Bio, working together to accelerate our market presence and drive innovation.”

    Carlson joins Deep Bio’s team, alongside a distinguished advisory board comprising industry leaders such as Michael Bonham, MD, PhD, the former Chief Medical Officer (CMO) of Proscia, and Kamala Maddali, DVM, PhD, the founder and CEO of Health Collaborations, an AI-based precision medicine consulting firm.

    Dr. Bonham is a respected board-certified anatomic pathologist who has garnered much recognition for his leadership pioneering developments in digital pathology. Prior to joining Deep Bio, his previous roles include Chief Medical Officer at Proscia, Head of Pathology at Driver, and Clinical Director of Pathology at Genomic Health. Throughout his career, Dr. Bonham has demonstrated expertise in the development and implementation of digital pathology software, genomic test development, and strategic clinical partnerships.

    Dr. Kamala Maddali, the founder and CEO of Health Collaborations, brings over 17 years of experience in precision medicine and clinical trials in oncology. She has held key leadership roles and served as a commercial executive for many Fortune 500 companies, including Quest Diagnostics, Merck, and Quintiles, where she fostered strategic partnerships and relationships with key opinion leaders.

    “As the global digital pathology market continues to grow, Deep Bio is actively exploring opportunities for international expansion and market penetration,” said Kim. “Grant’s expertise across the diagnostics and healthcare industries will be integral to accelerating commercial growth and innovative product development at Deep Bio.”

    About Deep Bio
    Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve the efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.

    DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr

    Deep Bio Secures Spot in South Korean Government’s Prestigious “Super Gap Startup 1000+” Program

    Posted on by Deepbio

    An award ceremony was held on July 4th, where Director Byeonggweon Lee from the Korean Ministry of SMEs and Startups (MSS) presented a plaque and expressed confidence in Deep Bio’s potential.

    SEOUL, SOUTH KOREA (PRWEB) JULY 07, 2023 – Deep Bio Inc., a leader in artificial intelligence (AI)-powered cancer diagnostics, has been selected for the South Korean government’s “Super Gap Startup 1000+” program. As a result of this selection, Deep Bio will receive up to 600 million KRW in funding over the next three years to drive its commercialization efforts.

    An award ceremony was held on July 4th, where Director Byeonggweon Lee from the Korean Ministry of SMEs and Startups (MSS) presented a plaque and expressed confidence in Deep Bio’s potential. “We hold high expectations for Deep Bio’s ability to revolutionize healthcare through their exceptional technological prowess.” He affirmed his commitment to supporting companies like Deep Bio by adding, “I will prioritize the needs of these innovative enterprises and ensure their growth by lending an ear to voices in this field.”

    The “Super Gap Startup 1000+” program is a national initiative aimed to foster high-tech startups that demonstrate unparalleled technological capabilities across 10 key industries. A super gap refers to a wide lead a market leader has over its competitors. Startups were selected based on rigorous evaluations conducted by a distinguished panel of experts from academia, industry, and investment firms. This program, backed by public-private partnerships, has earmarked unprecedented funding of over 2 trillion KRW over the next 5 years. Deep Bio’s selection for this highly competitive program validates its innovative AI-powered cancer diagnostic technology.

    “We are honored to be selected for the Super Gap Startup 1000+” program,” said Sun Woo Kim, the CEO and Founder of Deep Bio. “This selection is a testament to our innovative technology and our unwavering dedication to advancing unmet needs in not only digital pathology but in the wider landscape of healthcare. We will use this funding to accelerate our commercialization efforts and bring our products to more patients around the world.”

    Deep Bio’s pioneering technology utilizes AI to identify and categorize cancer cells in digitized biopsy images. Their diagnostic software tools aim to optimize cancer diagnostic workflows, empowering pathologists to enhance accuracy and reduce turnaround times, ultimately improving patient outcomes.

    Deep Bio has already obtained regulatory approval for two of its AI-powered cancer diagnostic software in South Korea. In 2020, they received clearance for DeepDx®-Prostate, a software that aids pathologists in diagnosing prostate cancer by detecting malignant lesions. In 2021, they obtained regulatory clearance for DeepDx®-Prostate Pro, a software that assists pathologists in grading and measuring tumors in prostate biopsies.

    As a trailblazer in AI-based pathology image analysis and cancer diagnostic software in Korea, Deep Bio continues to expand its global presence through partnerships with digital pathology platform providers in the US, Europe, and India. The company also engages in collaborative research with leading US research institutions, including Stanford Medical School and Harvard Dana-Farber Cancer Institute. Deep Bio’s groundbreaking clinical research results have been published in prestigious medical journals, such as Cancers and npj Digital Medicine.

    About Deep Bio
    Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve the efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.

    DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr

    Deep Bio’s AI Algorithm Helps Risk Stratification for Prostate Cancer

    Posted on by Deepbio

    Collaborative research by Deep Bio and Dr. Lotan research team at Johns Hopkins Medicine was revealed at AUA 2023

    SEOUL, SOUTH KOREA (PRWEB) MAY 11, 2023 – Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that Dr. Lotan from Johns Hopkins Medicine presented their collaborative research which utilized the deep learning-based algorithm for prostate cancer diagnosis support at a podium session in the American Urological Association (AUA) annual meeting 2023.

    This joint research compared human pathologists and an AI algorithm in grading prostate biopsy specimens to predict biochemical recurrence after radical prostatectomy. Gleason score is one of the key elements to grade prostate cancer and can lead to different clinical decisions. For example, even though 3+4 and 4+3 Gleason scores are identical Gleason score 7s, each has a different prognosis. Gleason 3+4 requires more than active surveillance but tends to fare much better in prognosis than Gleason 4+3.

    The study reassessed the diagnoses of 284 patients initially diagnosed as Gleason grade group 2 (Gleason score 3+4) and underwent radical prostatectomy at Johns Hopkins Medicine from 2000 to 2014. This cohort is one of the most challenging cohorts to diagnose since many cases diagnosed 3+4 before could be downgraded to 3+3 or upgraded to 4+3. Johns Hopkins Medicine also has up to 14 years of follow-up data on the patients (an average of 4 years of follow-up) and approximately 16% of the patients went through recurrence of prostate cancer. As the ISUP guidelines have changed in those periods, all of these biopsies were re-graded by two expert genitourinary pathologists and a third expert genitourinary pathologist served as a tiebreak for discrepant reads. To compare human pathologists and AI algorithms, Deep Bio’s AI-based prostate cancer diagnosis support software DeepDx® Prostate analyzed all the biopsies to provide Gleason grades as well.

    The results showed poor agreements between the two pathologists, generating a kappa of 0.17 while grading between the consensus pathology read and the AI algorithm generated a slightly higher kappa of 0.33. Importantly, however, the study suggested that the algorithm can act as a tool that stratifies patients for subsequent biochemical recurrence after radical prostatectomy. This risk stratification has the potential to prevent a lot of unnecessary surgeries and aid in choosing between treatment modalities.

    “It is a meaningful milestone for Deep Bio to conduct a joint research with Johns Hopkins Medicine, one of the top global universities, and the findings are remarkable for prostate cancer diagnosis using AI,” said Sun-Woo Kim, CEO of Deep Bio. “As precise diagnosis and personalization have become the crucial factors in deciding medical decisions for medical professionals, we will focus on bringing innovative deep learning technologies that can unlock new insights in cancer diagnosis and treatment” added he.

    Deep Bio continues to focus on not only AI diagnostics but also R&D and presenting the results in various international conferences and events. The company also continues to build its presence in the global market through collaboration with overseas digital pathology solution providers in the US, Europe, and India.

    About Deep Bio
    Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.

    DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.kr

    [Abstract] ASCO 2023 – Validation of AI-based postoperative nomograms for biochemical recurrence in prostate adenocarcinoma

    Posted on by Deepbio

    Authors:
    JaeHeon Lee, Tae-Yeong Kwak, Joonyoung Cho, Sun Woo Kim, Hyeyoon Chang, Hong Koo Ha

    Organizations
    Deep Bio Inc., Seoul, South Korea, Pusan National University, Pusan, South Korea

    Background
    After radical prostatectomy (RP), a steep increase in PSA level is an early sign of the disease progression in prostate cancer, which is known as biochemical recurrence (BCR). The risk of BCR can be evaluated based on a combination of clinicopathological factors, and the patient’s Gleason score plays a significant role. However, this scoring system may have lower consistency due to interobserver reproducibility in classifying Gleason Patterns (GP) as well as in quantifying the amount of each GP. We developed AI-based nomograms, with the aim of investigating their prognostic efficacy.

    Methods
    In this study, digitized whole-slide images (WSIs) of H&E-stained prostatectomy specimens and clinical follow-up information were obtained from two sources: Pusan National University Hospital (PNUH, n = 967, event = 342) from 2010 to 2021 with the median follow-up being 3.7 years, and The Cancer Genome Atlas (TCGA, n = 352, event = 79) from 2000 to 2013 with the median follow-up 2.6 years. We used the DeepDx Prostate – RP, an AI-based prostate cancer Gleason grading model, to compute a pixel-wise probability map of each GP in WSIs. Then, a weighted sum of the probabilities and GPs was calculated for each pixel. The proposed slide-level score (AI score) was then determined by averaging them across all pixels in WSI, resulting in a value ranging from 3 to 5. Also, patients were divided into five groups using AI score thresholds (3.1, 3.5, 3.9, and 4.1), and five binary variables (AI score group 1-5) were generated, where a value of 1 indicates a patient’s categorization into a group. To evaluate predictability we created new nomograms incorporating AI scores based on existing nomograms: MSKCC and CAPRA-S. Unlike the original nomograms, the proposed nomograms do not include the Grade Group (GG) made by pathologists. Then, we fitted a Cox regression model on one of two datasets using the original and newly formed nomograms, and validated on the other dataset reporting the concordance index (c-index). Confidence intervals for the c-index were generated via the non-parametric bootstrap resampling with 9,999 samples.

    Results
    The table shows the prognostic performance of sets of clinicopathological factors and demonstrates that the proposed AI score improved the predictive power. The nomograms with AI score group 1-5 outperformed the original nomograms, as shown in (d).

    Conclusions
    In conclusion, we developed the AI-based nomograms which can improve the accuracy of predicting the biochemical recurrence in prostate cancer compared to the existing nomograms.